Susquehanna International Group
RETA

Susquehanna International Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Susquehanna International Group’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-84,059
Closed -$8.57M – 13347
2023
Q2 		$8.57M Sell
84,059
-17,811
-17% -$1.69M ﹤0.01% 2713
2023
Q1 		$9.26M Buy
101,870
+86,819
+577% +$5.09M ﹤0.01% 2559
2022
Q4 		$572K Buy
15,051
+6,628
+79% +$228K ﹤0.01% 7505
2022
Q3 		$212K Buy
+8,423
New +$233K ﹤0.01% 10698
2021
Q4 		– Sell
-5,096
Closed -$394K – 14182
2021
Q3 		$513K Buy
5,096
+731
+17% +$85.7K ﹤0.01% 9340
2021
Q2 		$618K Sell
4,365
-75,333
-95% -$8.51M ﹤0.01% 9062
2021
Q1 		$7.95M Buy
79,698
+48,107
+152% +$5.61M ﹤0.01% 3149
2020
Q4 		$3.9M Sell
31,591
-60,130
-66% -$7.9M ﹤0.01% 3856
2020
Q3 		$8.94M Buy
91,721
+33,833
+58% +$4.23M ﹤0.01% 2317
2020
Q2 		$9.03M Buy
57,888
+31,562
+120% +$4.8M ﹤0.01% 2251
2020
Q1 		$3.8M Sell
26,326
-37,352
-59% -$7.21M ﹤0.01% 2937
2019
Q4 		$13M Buy
63,678
+31,665
+99% +$5.78M ﹤0.01% 1814
2019
Q3 		$2.57M Buy
32,013
+23,795
+290% +$2.02M ﹤0.01% 3751
2019
Q2 		$775K Buy
+8,218
New +$710K ﹤0.01% 6277

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's RETA Position: Q3 2023 in Review

Susquehanna International Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 84,059 shares — an estimated $8.57M sold.

Susquehanna International Group first reported a position in RETA in Q2 2019 and held it in 14 quarters. The position peaked at $13M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Susquehanna International Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Susquehanna International Group sold 84,059 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.57M.
  • Susquehanna International Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 14 quarters.
  • Susquehanna International Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $13M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.